|
Patent landscape, scope, and claims summary: |
Executive summary
US Patent 10,105,436 claims a combination therapy: an oncolytic vaccinia/poxvirus administered with a cellular adipose stromal product (adipose stromal cells and, in dependent claims, adipose-derived stromal vascular fraction (SVF)), with optional scope for cell genetic modification (artificial chromosome/virus/plasmid) and for viral engineering (heterologous gene product). Independent claim 1 is broad on cancer type (solid tumor and hematologic malignancy) and virus type (vaccinia virus). The estate’s enforceability typically turns on three fault lines: (i) whether accused products use vaccinia or poxvirus, (ii) whether the accused “adipose stromal” component is within the claim definition (cells vs SVF; autologous vs allogeneic), and (iii) whether the accused dosing/combination timing and mixture are practiced in vivo vs ex vivo. Claims 2 and 4–6 plus 7–9 create carve-ins for engineered cells and engineered viruses, and carve-outs for viruses lacking heterologous nucleic acid. Claims 15–26 broaden into compositions combining smallpox vaccine with adipose-derived SVF, which can be easier to assert than method-of-use in certain infringement theories.
Critical claim coverage and risk
- Highest-risk practice (most likely to read): a regimen where a vaccinia-based oncolytic virus (including ACAM2000 or NYCBOH strains named in the claims) is used clinically/experimentally in combination with adipose stromal cells/SVF, including where virus and cells are co-cultured or mixed before dosing.
- Main design-around levers: use a non-pox non-vaccinia oncolytic virus; avoid adipose-derived stromal cells/SVF (use different stromal sources); avoid the “combination” as claimed (separate administration without mixing/co-culture may still infringe depending on how “comprising administering… comprising…” is construed).
- Patent strength: enforceability depends on novelty and written-description/support for broad virus strain lists and for engineered variants (artificial chromosomes, SVF composition). Without the file history and specification, patent-claim scope can be wide but litigation outcomes typically hinge on claim construction and prior art.
What patents protect US Patent 10,105,436’s vaccinia-oncolytic virus plus adipose stromal cell strategy?
US Patent 10,105,436 covers combination therapy between:
- an oncolytic virus that is a vaccinia virus (Claim 1) and, separately, a poxvirus (Claim 3), and
- a composition comprising an adipose stromal cell, including adipose-derived SVF (Claims 12–14).
Core independent claim 1: what it actually covers
Claim 1 requires all elements:
- Method: treating a solid tumor or hematologic malignancy in a subject
- Administration: administer
- an oncolytic virus
- and a composition comprising an adipose stromal cell
- Virus limitation: the oncolytic virus is a vaccinia virus
This is a classic two-component combination claim. In practice, that means infringement arguments commonly focus on:
- whether the oncolytic virus is vaccinia (not merely “poxvirus-like”)
- whether the adipose component is adipose stromal within claim scope
- whether both are administered as part of the treating regimen
How dependent claims expand or narrow coverage
Key dependent claim clusters:
- Cell engineering: Claim 2 adds that the adipose stromal cell comprises an artificial chromosome, virus or plasmid.
- Virus engineering: Claim 4 excludes heterologous nucleic acid encoding heterologous product; Claim 9 includes that the oncolytic virus encodes a heterologous gene product.
- Specific strain/identity: Claims 5–6 constrain to attenuated NYCBOH strain, with identity to deposits ATCC VR-118 or CJ-MVB-SPX.
- Named strain list: Claim 7 lists numerous vaccinia strains/derivatives including ACAM1000, ACAM2000, Dryvax, Lister, MVA, Tian Tan, Copenhagen, Western Reserve, Dairen, Ikeda, LC16M8, Wyeth, IHD-J, IHD-W, Brighton, Dairen I, Connaught (with some repeats in the text provided).
- Tumor types: Claim 8 adds specific cancers (glioblastoma, breast, lung, prostate, colon, ovarian, neuroblastoma, CNS tumor, melanoma).
- Population: Claim 10 covers humans; Claim 11 adds pediatric patients.
- SVF: Claims 12–14 specify adipose-derived SVF and autologous use, and add the culture-together in vitro practice.
- Route and mixing: Claim 21 (virus routes), Claim 22 (cell routes), Claim 23 (virus mixed with adipose stromal composition prior to administration).
- Composition claims: Claims 15, 20, 25, 26 describe compositions: smallpox vaccine + adipose-derived SVF.
How broad are the cancer, virus, and cell definitions in claims 1–28?
Claim breadth is a function of three independent axes: cancer type, virus type/strain, and cell definition.
Cancer coverage
- Claim 1: solid tumors and hematologic malignancies.
- Claim 27: confirms “solid tumor” limitation.
- Claim 8: enumerated solid tumors.
This makes the patent relevant across oncology pipelines that use vaccinia/pox oncolytics plus adipose stromal products.
Virus coverage
- Claim 1: vaccinia virus.
- Claim 3: poxvirus (broader in theory, but dependent on claim dependency structure in the full patent).
- Claim 5–7: provides high-specificity anchors (NYCBOH strain deposits and a long vaccinia strain list).
This is a strong coverage posture because:
- the patent is not limited to a single commercial oncolytic (e.g., ACAM2000),
- but it is still restricted to vaccinia/pox rather than “any oncolytic virus,” which is the main design-around.
Adipose stromal definition
- Claim 1: “composition comprising an adipose stromal cell.”
- Claim 12: adipose-derived stromal vascular fraction (SVF).
- Claim 13: SVF is autologous.
SVF is a key interpretive battleground. SVF is typically a mixed-cell fraction (endothelial cells, pericytes, immune cells, progenitors). Whether a commercially prepared SVF product qualifies as “adipose stromal cell” depends on claim construction and specification support.
When does US Patent 10,105,436 lose exclusivity?
No exclusivity timeline can be computed from the claim text alone. Patent term and any extension depend on:
- application filing date,
- any PTA,
- continuation status,
- and whether there are relevant FDA-related extensions.
Without those docket details, exclusivity cannot be stated accurately.
How strong is the patent estate for vaccinia-oncolytic regimens using adipose-derived SVF?
US 10,105,436 strength is driven by how reliably it maps onto real-world product attributes and clinical protocol elements.
Most enforceable footholds
- Explicit virus genus and brand analogs
Claim 7 names strains including ACAM2000 (and Dryvax and ACAM1000). If an accused regimen uses ACAM2000 or a listed strain, infringement analysis is likely to be straightforward.
- Explicit cell product category
Claim 12 captures adipose-derived SVF. Many cell therapy companies market SVF products as a standard adipose stromal compartment.
- Specific practice elements
Claim 14 (culture together in vitro) and Claim 23 (mix virus with adipose stromal composition prior to administration) can support stronger “step” infringement theories when accused workflows match.
Potential vulnerability
- Breadth vs support: method claim 1 is broad across tumor types and virus strain list. In litigation, wide scope is tested against the specification’s enabling disclosure and written description.
- Claim 4 and Claim 9 internal tension: Claim 4 excludes heterologous nucleic acid; Claim 9 includes it. The patent may rely on different embodiments; if construction blurs, parties may argue lack of clear boundaries.
- SVF heterogeneity: if the accused “adipose stromal” is a purified subset (e.g., cultured adipose-derived mesenchymal stromal cells) and not SVF, defendants may argue it falls outside “adipose-derived SVF” dependent claims and possibly outside “adipose stromal cell” depending on definition in the specification.
Which companies are likely exposed by US Patent 10,105,436?
The claim text identifies virus types (vaccinia oncolytic; smallpox vaccine strains including ACAM2000) and adipose stromal/SVF. Exposure therefore clusters around developers combining:
- vaccinia-derived oncolytic viruses with
- adipose-derived stromal products (SVF or adipose stromal cells)
in oncology settings.
However, company-specific exposure requires Orange Book/FDA review and litigation docket mapping that is not provided in the prompt. Without that, naming defendants or litigants would be speculative.
What is the Orange Book status of US Patent 10,105,436?
No drug identifier, FDA application number, or NDA/BLA/Orange Book listing mapping is provided. US Patent numbers are not inherently tied to an Orange Book entry without linkage to an FDA product and application.
What generic entry risks exist for a vaccinia + adipose stromal/SVF combination therapy?
Generic “entry” risk depends on whether the therapy is an FDA-approved drug with an Orange Book listing, and whether it has a legally protected composition or method-of-use basis. For combination regimens with live viruses and cell components:
- “generic” concepts are often replaced by biosimilar-like or follow-on biologic/biologic product frameworks and/or cell therapy regulatory frameworks.
- For Paragraph IV-style challenges, the trigger is typically an Orange Book listing and an ANDA letter structure, neither of which is identified here.
Accordingly, a credible launch-risk analysis cannot be produced from claim text alone.
What formulations are protected by US Patent 10,105,436?
US 10,105,436 includes explicit composition claims that can be easier targets than method-of-use claims.
Composition claim 15
Claim 15: composition comprising
- (a) smallpox vaccine
- (b) adipose-derived stromal vascular fraction (SVF)
This is a formulation/composition claim combining a vaccine/virus component and an adipose cell fraction.
Composition narrowing dependent claims
- Claim 20: smallpox vaccine is Dryvax, ACAM2000 or ACAM1000.
- Claim 25: smallpox vaccine is ACAM2000.
- Claim 26: smallpox vaccine is an attenuated strain selected from a list including Dryvax, ACAM1000, ACAM2000, and others including MVA, NYCBOH, Dairen, Ikeda, LC16M8, Western Reserve Copenhagen, Tashkent, Wyeth, IHD-J/IHD-W, Brighton, Dairen I, Connaught.
If a product is sold as a pre-packaged combination or prepared under a protocol matching these attributes, composition claim coverage becomes salient.
What method-of-use elements are required for infringement: routes, mixing, and in vitro co-culture?
US 10,105,436 contains several method-step dependent limitations that can be outcome-determinative.
Routes (Claim 21 for virus; Claim 22 for cells)
Virus route options:
- intratumoral, intravenous, intraperitoneal, intrathecal, intraventricular, intraarticular, intraventricular, intraocular (the provided text includes intraventricular and lists both intraventricular and intraventricular again; the intent is multiple CNS and local routes).
Cell route options:
This supports broad clinical administration patterns.
Mixing and ex vivo handling
- Claim 14: virus and adipose stromal cells are cultured together in vitro prior to administration.
- Claim 23: virus is mixed with the adipose stromal composition prior to administration.
If an accused protocol administers virus and cells separately without mixing and without co-culture, infringement may still occur under Claim 1 (since Claim 1 does not require mixing), but dependent claims strengthen proof when steps match.
How do the engineered-virus and engineered-cell sub-claims affect design-around strategies?
US 10,105,436 includes mutually framing engineered features.
Virus genetic content
- Claim 4: oncolytic virus does not comprise heterologous nucleic acid encoding heterologous product
- Claim 9: oncolytic virus encodes a heterologous gene product
This suggests the patent asserts coverage for both “unarmed/limited” vaccinia and “armed” vaccinia, depending on embodiment. For design-around, the key is not whether the virus is “armed,” because the patent appears to cover both categories. Instead, design-around typically shifts to:
- use a non-vaccinia/pox oncolytic platform, or
- remove the adipose stromal/SVF component.
Cell genetic content
- Claim 2: adipose stromal cell comprises an artificial chromosome, virus or plasmid
- Claim 24: adipose stromal cell is modified with a virus, plasmid or artificial chromosome
These claims target engineered cell approaches, but are not necessary to hit Claim 1’s base combination.
How does US Patent 10,105,436 compare with typical oncolytic virus patent strategies?
US 10,105,436 is notable because it combines:
- an oncolytic virus defined by a vaccinia/pox constraint, and
- a host-cell component defined by an adipose stromal/SVF constraint,
rather than focusing solely on viral genetic modifications or a single tumor biomarker.
That combination-of-systems structure often creates:
- more entry points for infringement (virus platform plus cell product),
- more leverage for licensing (either component potentially licensed depending on manufacturing and clinical protocol),
- and more complex enforcement because the accused regimen must be mapped across both biological components.
Key Takeaways
- US Patent 10,105,436 is a combination therapy patent: vaccinia/pox oncolytic virus + adipose stromal cells/SVF.
- Independent Claim 1 is broad on cancer type and is restricted primarily by vaccinia virus and adipose stromal cell.
- Dependent claims add enforcement hooks: NYCBOH strain identity deposits, long vaccinia strain lists including ACAM2000, SVF and autologous use, in vitro co-culture, and mixing prior to administration.
- Composition claims (notably Claim 15) combine smallpox vaccine + adipose-derived SVF, which can support infringement theories focused on product preparation rather than only clinical steps.
- Actionable design-around typically requires avoiding either vaccinia/pox or the adipose stromal/SVF component; switching between “armed” and “unarmed” vaccinia is unlikely to escape because both engineered and non-heterologous embodiments are claimed.
FAQs
- Does Claim 1 require co-culturing or mixing the virus with adipose stromal cells before dosing?
- Is “adipose-derived SVF” the same as “adipose stromal cells” for infringement purposes?
- If an accused regimen uses a vaccinia strain not listed in Claim 7, does Claim 1 still apply?
- Do Claims 4 and 9 create separate product categories that can be used to invalidate or narrow infringement theories?
- If the regimen uses an oncolytic poxvirus other than vaccinia, which claims remain potentially relevant?
References (APA)
- U.S. Patent No. 10,105,436.
More… ↓
⤷ Start Trial
|
